Alnylam Pharmaceuticals, Inc. ALNY
Healthcare · Biotechnology · United States · Nasdaq-100
Based on the available data, Alnylam Pharmaceuticals, Inc. gets an algorithmic score of 54/100. It trades at 254.07 $, with a bearish technical trend (RSI 54.4) and 47.3% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (96.6%): generates strong profit on equity.
- Sustained revenue growth (53.0% compound annual).
- Low beta (0.39): defensive profile.
Weaknesses
- High leverage (debt/equity 221%): rate-sensitive.
Fundamentals
| P/E | 44.26 |
| Forward P/E | 20.37 |
| PEG | 0.32 |
| P/B | 25.09 |
| EV/EBITDA | 31.93 |
| P/S | 7.08 |
| ROE % | 96.56 |
| ROA % | 12.34 |
| Gross margin % | 79.65 |
| Operating margin % | 17.93 |
| Net margin % | 16.13 |
| Revenue growth % (y/y) | 66.90 |
| Revenue CAGR % | 52.98 |
| Debt/Equity % | 220.62 |
| Current ratio | 3.06 |
| FCF yield % | 1.37 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | +7.2 % |
| 3 months | -15.6 % |
| 6 months | -19.6 % |
| YTD | -36.5 % |
| 1 year | -43.1 % |
| 3 years | +48.1 % |
| 5 years | +38.0 % |
Risk
| 1-year volatility | 47.3 % |
| Beta | 0.39 |
| 5-year max drawdown | -58.2 % |
| Sharpe 1A | -1.02 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.